Varicella in Pediatric Patients
- 1 July 1993
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 27 (7-8) , 938-949
- https://doi.org/10.1177/106002809302700723
Abstract
OBJECTIVE: To summarize the literature describing the epidemiology, transmission, clinical manifestations, diagnosis, treatment, and prevention of varicella in the pediatric population. DATA SOURCES: A literature search of English-language articles from 1982 to 1992 using MEDLINE and bibliographies of relevant articles. The search term used was varicella. STUDY SELECTION: All review articles and original studies addressing the epidemiology, transmission, clinical manifestations, complications, diagnosis, treatment, and prevention of varicella in pediatric patients were reviewed. Emphasis was placed on controlled studies done in the US. DATA EXTRACTION: Data from human studies were extracted by the authors and evaluated according to patient population, sample size, dosing regimen, efficacy, and safety. DATA SYNTHESIS: Varicella-zoster virus is a highly contagious virus that produces a common and costly disease in the pediatric population. The primary manifestation of varicella is the eruption of vesicular lesions. In most cases varicella is benign, but it can be associated with serious complications. Diagnosis is based primarily on clinical findings. Otherwise healthy children have traditionally received only symptomatic treatment for varicella, but recent literature suggests that antiviral therapy may be useful in these patients. Immunocompromised patients benefit from both symptomatic and antiviral therapy. Isolation and varicella-zoster immune globulin are used to prevent varicella. In the future, varicella vaccine will play an important role in preventing the disease. Varicella vaccine has been shown to be immunogenic and clinically effective in both healthy and immunocompromised children. Adverse reactions associated with the vaccine include fever, injection-site reactions, and rash. Although zoster can follow vaccination, the incidence appears to be lower in vaccinated individuals. Preliminary studies have shown that the vaccine provides protection from varicella-zoster virus for an extended period of time. CONCLUSIONS: Varicella is a common, usually benign disease of childhood. All patients may benefit from symptomatic therapy. Current literature does not support the use of antiviral therapy in all pediatric patients with varicella. When commercially available, varicella vaccine will play an important role in prevention. Long-term studies are needed to fully assess the risk of developing varicella and zoster following vaccination.Keywords
This publication has 73 references indexed in Scilit:
- Acyclovir treatment of varicella in otherwise healthy adolescentsThe Journal of Pediatrics, 1992
- Acyclovir treatment of varicella in otherwise healthy childrenThe Journal of Pediatrics, 1990
- Live attenuated varicella vaccine: Evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virusThe Journal of Pediatrics, 1990
- Acetaminophen: More harm than good for chickenpox?The Journal of Pediatrics, 1989
- Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccineThe Journal of Pediatrics, 1989
- Intrauterine Infection with Varicella-Zoster Virus after Maternal VaricellaNew England Journal of Medicine, 1986
- Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulinThe Journal of Pediatrics, 1984
- Intravenous acyclovir therapy for varicella in immunocompromised childrenThe Journal of Pediatrics, 1984
- Acyclovir therapy of chickenpox in immunosuppressed children—A collaborative studyThe Journal of Pediatrics, 1982
- Vidrabine therapy of varicella in immunosuppressed patientsThe Journal of Pediatrics, 1982